{"title": "Akute Blasenentz\u00fcndung \u2013 Behandlung ohne Antibiotika", "author": "PHC Primary; Hospital Care; Olivia Altwegg; Saskia Weisskopf; Marianne Mattm\u00fcller; Patricia Spieler; Tanja Grandinetti; Anina Hilfiker; Peter Christiaan Carp; Angela Huttner; Alexandra Calmy; Barbara Hasse; Gisela Etter; Philip Tarr", "url": "https://phc.swisshealthweb.ch/de/article/doi/phc-d.2020.10179", "hostname": "swisshealthweb.ch", "description": "Jahrzehntelange Erfahrung und neue randomisierte Studien zeigen, dass eine unkomplizierte Blasenentz\u00fcndung bei sonst gesunden, nicht schwangeren Frauen grunds\u00e4tzlich erfolgreich ohne Antibiotika behandelt werden kann. Dies sollte neu zum Standard werden. Wichtig sind eine sorgf\u00e4ltige Diagnosestellung, gute Kommunikation, gute symptomlindernde Behandlung und eine niederschwellige Nachkontrolle bei Verschlechterung, um diejenigen Frauen (max. 5%) zu erkennen, die ohne Antibiotika eine Pyelonephritis entwickeln k\u00f6nnten.", "sitename": "Olivia Altwegg,Saskia Weisskopf,Marianne Mattm\u00fcller,Patricia Spieler,Tanja Grandinetti,Anina Hilfiker,Peter Christiaan Carp,Angela Huttner,Alexandra Calmy,Barbara Hasse,Gisela Etter,Philip Tarr", "date": "2020-01-08", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "1 Tarr P, Baumann K, Walln\u00f6fer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfektionen, Teil 1: HWI in der Praxis. Swiss Medical Forum \u2013 Schweizerisches Medizin-Forum. 2013; 13(24):467\u2013471. 10.4414/smf.2013.01543\n2 Kronenberg A, B\u00fctikofer L, Odutayo A, M\u00fchlemann K. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017. 10. 10.1136/bmj.j4784\n3 Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 2019; 25(8):973\u2013980. 10.1016/j.cmi.2019.01.011\nLiteratur\n1 Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Review of Vaccines. 2012;11(6):663\u201376. 10.1586/erv.12.36.\n2 Hooton TM. Uncomplicated Urinary Tract Infection. N Engl J Med. 2012;366(11):1028\u201337. 10.1056/NEJMcp1104429.\n3 Datta R, Juthani-Mehta M. Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis. JAMA. 2018;319(17):1771. 10.1001/jama.2018.4654.\n4 Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Internal Medicine. 2018;178(11):1509\u201315. 10.1001/jamainternmed.2018.4204.\n5 Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ. 2010;340(feb05 1):c199\u2013c199. 10.1136/bmj.c199.\n6 Tarr P, Baumann K, Walln\u00f6fer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfe ktionen, Teil 1: HWI in der Praxis. Swiss Medical Forum \u2013 Schweizerisches Medizin-Forum. 2013;13(24):467\u201371. 10.4414/smf.2013.01543.\n7 Schwenke J, Schaub R, Tarr P. Update Antibiotikaresistenzen 2018 f\u00fcr die Praxis. Primary and Hospital Care: Allgemeine Innere Medizin. 2018;376\u201380:10.4414/phc-d.2018.01839.\n8 Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011;52(5):e103\u2013e120. 10.1093/cid/ciq257.\n9 Hasse B, Huttner A, Huttner B, Egger M, Zanetti G, Marschall J, et al. Behandlung von unkomplizierten Harnwegsinfektionen. 2014; . Available from:\n[https://www.researchgate.net/publication/278748193_Behandlung_von_unkomplizierten_Harnwegsinfektionen10.5167/uzh-106675](https://www.researchgate.net/publication/278748193_Behandlung_von_unkomplizierten_Harnwegsinfektione)\n.\n10 Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018;319(17):1781\u20139. 10.1001/jama.2018.3627.\n11 Wijma RA, Koch BCP, Gelder T van, Mouton JW. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers. Clinical Microbiology and Infection. 2018;24(5):528\u201332. 10.1016/j.cmi.2017.08.023.\n12 Palou J, Angulo J, Ram\u00f3n de Fata F, Garc\u00eda-Tello F, Gonz\u00e1lez-Enguita C, Boada A, et al. Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection. Actas Urol\u00f3gicas Espa\u00f1olas. 2012;37(3):147\u2013155. 10.1016/j.acuro.2012.06.007.\n13 Qiao L-D, Zheng B, Chen S, Yang Y, Zhang K, Guo H-F, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157. 10.1136/bmjopen-2013-004157.\n14 Giancola S, Mahoney M, Hogan M, Raux B, McCoy C, Hirsch E. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes. Chemotherapy. 2017;62(2):100\u20134. 10.1159/000449422.\n15 Kronenberg A, B\u00fctikofer L, Odutayo A, M\u00fchlemann K. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017;10. 10.1136/bmj.j4784.\n16 Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Frontiers in Microbiology [Internet]. 2016 [cited 2019 Apr 7]; 6. Available from:\n[http://journal.frontiersin.org/Article/10.3389/fmicb.2015.01543/abstract10.3389/fmicb.2015.01543](https://www.ncbi.nlm.nih.gov/pubmed/26793178)\n.\n17 Caballero S, Carter R, Ke X, Su\u0161ac B, Leiner IM, Kim GJ, et al. Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae. Baumler AJ, editor. PLOS Pathogens. 2015;11(9):e1005132. 10.1371/journal.ppat.1005132.\n18 Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Medicine. 2016;8(1):39. 10.1186/s13073-016-0294-z.\n19 Knottnerus BJ, Geerlings SE, Moll van Charante EP, Riet G ter. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Family Practice. 2013;14(1):71. 10.1186/1471-2296-14-71.\n20 Harbarth S, Balkhy HH, Goossens H, Jarlier V, Kluytmans J, Laxminarayan R, et al. Antimicrobial resistance: one world, one fight! Antimicrob Resist Infect Control. 2015;4(1):49. 10.1186/s13756-015-0091-2.\n21 World Health Organization, editor. Antimicrobial resistance: global report on surveillance [Internet]. Geneva, Switzerland: World Health Organization; 2014. Available from:\n[https://www.who.int/drugresistance/documents/surveillancereport/en/](https://www.who.int/drugresistance/documents/surveillancereport/en/)\n.\n22 Vollaard EJ, Clasener HA. Colonization Resistance. Antimicrobial Agents and Chemotharpy. 1994. 10.1128/AAC.38.3.409.\n23 Stewardson AJ, Ga\u00efa N, Fran\u00e7ois P, Malhotra-Kumar S, Del\u00e9mont C, Martinez de Tejada B, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clinical Microbiology and Infection. 2015;21(4):344.e1-344.e11. 10.1016/j.cmi.2014.11.016.\n24 Arag\u00f3n IM, Herrera-Imbroda B, Queipo-Ortu\u00f1o MI, Castillo E, Del Moral JS-G, G\u00f3mez-Mill\u00e1n J, et al. The Urinary Tract Microbiome in Health and Disease. European Urology Focus. 2018;4(1):128\u201338. 10.1016/j.euf.2016.11.001.\n25 Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract\u2014a role beyond infection. Nature Reviews Urology. 2015;12(2):81\u201390. 10.1038/nrurol.2014.361.\n26 Leydon GM, Turner S, Smith H, Little P, on behalf of the UTIS team. Women\u2019s views about management and cause of urinary tract infection: qualitative interview study. BMJ. 2010;340(feb05 1):c279\u2013c279. 10.1136/bmj.c279.\n27 Mangin D. How doctors deliver care is as influential as the treatment itself. BMJ. 2010;340:373\u2013374. 10.1136/bmj.c657.\n28 Finucane TE. \u2018Urinary Tract Infection\u2019 and the Microbiome. The American Journal of Medicine. 2017;130(3):e97\u2013e98. 10.1016/j.amjmed.2016.08.018.\n29 Tarr P, Baumann K, Walln\u00f6fer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfektionen, Teil 2: HWI im Spital sowie Alters- und Pflegeheim. Swiss Medical Forum \u2013 Schweizerisches Medizin-Forum. 2013;472\u20135. 10.4414/smf.2013.01546.\n30 Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D\u2019Elia C, et al. The Role of Asymptomatic Bacteriuria in Young Women With Recurrent Urinary Tract Infections: To Treat or Not to Treat? Clinical Infectious Diseases. 2012;55(6):771\u20137. 10.1093/cid/cis534.\n31 Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases. 2019;68. 10.1093/cid/ciy1121.\n32 Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The female urinary microbiome in urgency urinary incontinence. American Journal of Obstetrics and Gynecology. 2015;213(3):347.e1-347.e11. 10.1016/j.ajog.2015.07.009.\n33 Thomas-White KJ, Kliethermes S, Rickey L, Lukacz ES, Richter HE, Moalli P, et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. American Journal of Obstetrics and Gynecology. 2017;216(1):55.e1-55.e16. 10.1016/j.ajog.2016.07.049.\n34 Betschart C, Albrich W, Brandner S, Faltin D, Kuhn A, Surbek D, et al. Akute und rezidivierende Harnwegsinfektionen [Internet]. 2018. Available from:\n[https://www.sggg.ch/fileadmin/user_upload/58_Harnwegsinfekt_Juni_2018.pdf](https://www.sggg.ch/fileadmin/user_upload/58_Harnwegsinfekt_Juni_2018.pdf)\n.\n35 Deutsches \u00c4rzteblatt: EMEA schr\u00e4nkt Anwendung von Moxifloxacin und Norfloxacin deutlich ein [Internet]. Deutsches \u00c4rzteblatt. 2012. Available from:\n[https://www.aerzteblatt.de/nachrichten/51270/Leberschaeden-durch-Moxifloxacin-und-Levofloxacin](https://www.aerzteblatt.de/nachrichten/51270/Leberschaeden-durch-Moxifloxacin-und-Levofloxacin)\n.\n36 European Medicines Agency. EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections [Internet]. 2008. Available from:\n[https://www.ema.europa.eu/en/news/emea-recommends-restricted-use-oral-norfloxacin-containing-medicines-urinary-infections](https://www.ema.europa.eu/en/news/emea-recommends-restricted-use-oral-norfloxacin-containing-medicines-urinary-infections)\n37 G\u00e1gyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015; :h6544. 10.1136/bmj.h6544.\n38 Vik I, Bollestad M, Grude N, B\u00e6rheim A, Damsgaard E, Neumark T, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women\u2014A double-blind, randomized non-inferiority trial. Basu S, editor. PLOS Medicine. 2018;15(5):e1002569. 10.1371/journal.pmed.1002569.\n39 Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 2019;25(8):973\u201380. 10.1016/j.cmi.2019.01.011.\n40 Hofmann Y, Berger H, Wingeier B, Huber B, Boggian K, Hug-Batschelet H, et al. Behandlung der Streptokokken-Angina. Swiss Medical Forum \u2013 Schweizerisches Medizin-Forum. 23.\n41 Little P. Antibiotics or NSAIDs for uncomplicated urinary tract infection? BMJ. 2017;j5037. 10.1136/bmj.j5037.\n42 Wojnicz D, Kucharska AZ, Sok\u00f3\u0142-\u0141\u0119towska A, Kicia M, Tichaczek-Goska D. Medicinal plants extracts affect virulence factors expression and biofilm formation by the uropathogenic Escherichia coli. Urol Res. 2012;40(6):683\u201397. 10.1007/s00240-012-0499-6.\n43 Mutters NT, Mampel A, Kropidlowski R, Biehler K, G\u00fcnther F, B\u0103lu I, et al. Treating urinary tract infections due to MDR E. coli with Isothiocyanates \u2013 a phytotherapeutic alternative to antibiotics? Fitoterapia. 2018;129:237\u201340. 10.1016/j.fitote.2018.07.012.\n44 Marcon J, Schubert S, Stief CG, Magistro G. In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections. Infection [Internet]. 2019 [cited 2019 Nov 10]; . Available from:\n[http://link.springer.com/10.1007/s15010-019-01315-410.1007/s15010-019-01315-4](https://www.springermedizin.de/in-vitro-efficacy-of-phytotherapeutics-suggested-for-prevention-/16709178)\n.\n45 Garcia Larrosa A, Alexe O. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial. Clin Microbiol [Internet]. 2016 [cited 2019 Nov 10]; 05(01). Available from:\n[http://www.esciencecentral.org/journals/efficacy-and-safety-of-a-medical-device-versus-placebo-in-the-earlytreatment-of-patients-with-symptoms-of-urinary-tract-infection-2327-5073-1000233.php?aid=6702110.4172/2327-5073.1000233](https://www.esciencecentral.org/)\n46 Albrecht U, Goos K-H, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Current Medical Research and Opinion. 2007;23(10):2415\u201322. 10.1185/030079907X233089.\n47 Wagenlehner FM, Abramov-Sommariva D, H\u00f6ller M, Steindl H, Naber KG. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327\u201336. 10.1159/000493368.\n48 Vicariotto F. Effectiveness of an Association of a Cranberry Dry Extract, D-mannose, and the Two Microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in Women Affected by Cystitis: A Pilot Study. Journal of Clinical Gastroenterology. 2014;48:S96\u2013S101. 10.1097/MCG.0000000000000224.\n49 Del Popolo G, Nelli F. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. Arch Ital Urol Androl. 2018;90(2):101. 10.4081/aiua.2018.2.101.\n50 Cai T, Tiscione D, Cocci A, Puglisi M, Cito G, Malossini G, et al. Hibiscus extract, vegetable proteases and Commiphora myrrha are useful to prevent symptomatic UTI episode in patients affected by recurrent uncomplicated urinary tract infections. Arch Ital Urol Androl. 2018;90(3):203. 10.4081/aiua.2018.3.203.\n51 Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ. 2010;340(feb05 1):b5633\u2013b5633. 10.1136/bmj.b5633.\n52 Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, et al. Recurrent Urinary Tract Infections in Postmenopausal Women. Clinical Infectious Diseases. 2000;30(1):152\u20136. 10.1086/313596.\n53 Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, et al. Urinary tract infection among women aged 40 to 65: Behavioral and sexual risk factors. Journal of Clinical Epidemiology. 2001;9. 10.1016/s0895-4356(00)00352-8.\n54 Gharbi M, Drysdale JH, Lishman H, Goudie R, Molokhia M, Johnson AP, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ. 2019;l525. 10.1136/bmj.l525.\n55 Beetz R. Mild dehydration: a risk factor advertising and analytics partners in accordance with our Privacy Policy. You can manage your of urinary tract infection? preferences in \u201cManage Cookies\u201d. European Journal of Clinical Nutrition. 2003;57:52\u20138. 10.1038/sj.ejcn.1601902.\n56 Vyas S, Varshney D, Sharma P, Juyal R, Nautiyal V, Shrotriya V. An overview of the predictors of symptomatic urinary tract infection among nursing students. Ann Med Health Sci Res. 2015;5(1):54\u20138. 10.4103/2141-9248.149790.\n57 Grady D. Drinking More Water for Prevention of Recurrent Cystitis. JAMA Intern Med. 2018;178(11):1515. 10.1001/jamainternmed.2018.4195.", "language": null, "image": "https://phc.swisshealthweb.ch/fileadmin/_processed_/f/a/csm_10179_Schmuckbild_1170x450_295ec993a3.jpg", "pagetype": "article", "links": ["https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "#collapseSearch", "/de/article/doi/phc-d.2020.10179/", "/fr/article/doi/phc-f.2020.10179/", "https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "/de/", "/de/aktuelle-ausgabe/", "/de/archiv/", "/de/publizieren/", "/de/ueber-phc/", "https://www.swisshealthweb.ch/de/zeitschriften/", "https://shop.emh.ch/", "https://www.swisshealthweb.ch/de/encyclomed/", "https://events.emh.ch", "https://phc.swisshealthweb.ch/de/article/?tx_cs2services_teaser%5Baction%5D=serviceLinkHandler&tx_cs2services_teaser%5Bcontroller%5D=Services&tx_cs2services_teaser%5Bservice%5D=9&type=96529&cHash=957c22557b087f72957914479c8387b5", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "/de/article/doi/phc-d.2020.10179/", "/fr/article/doi/phc-f.2020.10179/", "https://events.emh.ch/", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", "https://shop.emh.ch/", null, "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2020/phc-d.2020.10179/phc-d-2020-10179.pdf", "#otherInfos", "/de/archiv/ausgabe/issue-doi/phc.2020.01/", "https://doi.org/10.4414/phc-d.2020.10179", "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2020/phc-d.2020.10179/phc-d-2020-10179.pdf", "https://www.researchgate.net/publication/278748193_Behandlung_von_unkomplizierten_Harnwegsinfektione", "https://www.ncbi.nlm.nih.gov/pubmed/26793178", "https://www.who.int/drugresistance/documents/surveillancereport/en/", "https://www.sggg.ch/fileadmin/user_upload/58_Harnwegsinfekt_Juni_2018.pdf", "https://www.aerzteblatt.de/nachrichten/51270/Leberschaeden-durch-Moxifloxacin-und-Levofloxacin", "https://www.ema.europa.eu/en/news/emea-recommends-restricted-use-oral-norfloxacin-containing-medicines-urinary-infections", "https://www.springermedizin.de/in-vitro-efficacy-of-phytotherapeutics-suggested-for-prevention-/16709178", "https://www.esciencecentral.org/", "https://emh.ch/en/emh/rights-and-licences/", "#top", null, null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "https://www.swisshealthweb.ch/de/informationen-und-services/qualitaetssicherung/", "https://www.swisshealthweb.ch/de/informationen-und-services/publizistische-leitlinien/", "https://www.swisshealthweb.ch/de/informationen-und-services/copyright/", "https://www.swisshealthweb.ch/de/informationen-und-services/newsletter/", "https://www.swisshealthweb.ch/de/verlag/ueber-emh/", "https://www.swisshealthweb.ch/de/verlag/inserieren/", "https://www.swisshealthweb.ch/de/verlag/jobs/", "https://www.swisshealthweb.ch/de/partner/", "https://www.swisshealthweb.ch/de/verlag/hilfe-und-kontakt/", "https://www.swisshealthweb.ch/de/agb/", "https://www.swisshealthweb.ch/de/verlag/impressum/", "https://www.swisshealthweb.ch/de/verlag/datenschutz/", "https://www.swisshealthweb.ch/de/verlag/disclaimer/", "javascript:void()"]}